COPENHAGEN and OSLO, September 1 /PRNewswire-FirstCall/ -- Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today announced that it has appointed two experienced biotech executives to head its management team. Dr Robert Burns, previously CEO of Celldex Therapeutics Inc., has today assumed overall responsibility for Affitech as its new Chief Executive Officer. Dr Alexander Duncan, previously SVP Biopharmaceuticals for Astra Zeneca - Medimmune, also joins Affitech today as Senior Vice President of Research and Development. Dr Robert Burns takes over the Affitech CEO role from Dr Achim Kaufhold who, having successfully completed the recent combination of Affitech and Pharmexa, is leaving the Company. Dr Martin Welschof, Managing Director of Affitech Research AS, Oslo, continues in post.
Robert Burns is an experienced biotech business executive. He joins
Affitech following the successful merger of Celldex Therapeutics and
NASDAQ-listed Avant Immunotherapeutics. Prior to Celldex, Robert was Director
of Technology Licensing at the Ludwig Institute for Cancer Research, where he
was played key leadership roles in the spin-out of 3 successful companies,
Piramed in the UK, Lymphatix in Finland and Recepta, an antibody therapeutics
business, in Brazil. Prior to that he was Commercial Director at both Oxford
Glycosciences and British Biotech. Robert is also non-executive Chairman of
Haemostatix, an early stage company specialising in blood clotting products.
Robert holds a BSc in Chemistry and a PhD in oligosaccharide analysis from
Alexander Duncan is a leading antibody research scientist and business
leader. At Astra Zeneca he was a member of AZ Discovery senior management
team and SVP Biopharmaceuticals. He led the Cambridge UK Discovery site,
previously Cambridge Antibody Technology (CAT), through its integration with
Medimmune. Prior to its acquisition by
|SOURCE Affitech AS|
Copyright©2009 PR Newswire.
All rights reserved